Faruqi & Faruqi Reminds ATyr Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 9, 2025 - ATYR

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against ATyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The firm is reminding investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against ATyr Pharma [4]. - The complaint alleges that ATyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroids [6]. Group 2: Drug Efficacy and Market Impact - In the EFZO-FIT study, Efzofitimod did not demonstrate a significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - Complete steroid withdrawal was achieved in 52.6% of patients treated with Efzofitimod versus 40.2% on placebo [7]. - Following the release of the study results, ATyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].